49 results about "Tumid Lupus Erythematosus" patented technology

The invention discloses a cycloalkane thiophthene derivative and pharmaceutically acceptable salts, metabolic products or prodrugs thereof. A compound can be used for treating diseases related with STAT3 (Signal Transducer and Activator of Transcription 3) activation, such as ovarian cancer, endometrial cancer, cervical cancer, breast cancer, colon cancer, pancreatic cancer, lung cancer, brain cancer, prostate cancer, kidney cancer, liver cancer, bladder cancer, oral cancer, sarcoma, prostate cancer, head and neck squamous cell carcinoma, neuroglioma, melanoma, lymphoma, leukemia, and renal fibrosis, pulmonary fibrosis, rheumatoid arthritis, hair growth, arthritis, psoriasis, lupus erythematosus, inflammatory lung diseases and inflammatory bowel diseases. (The formula is shown in the description.).

The invention provides an application of umbilical cord mesenchymal stem cells in preparation of formulation for treating lupus erythematosus, in particular to an application in preparation of formulation for treating recurrent systemic lupus erythematosus. The invention further provides a method of preparing umbilical cord mesenchymal stem cells of formulation capable of being used for treating the lupus erythematosus and a formulation composition having the stem cells. The umbilical cord mesenchymal stem cells prepared by the invention have the advantages of low immunoreaction risk, high activity, low residue, and the like, and the preparation cost is low.

The invention relates to a construction method of a systemic lupus erythematosus map model. The construction method comprises: setting a systemic lupus erythematosus group and a control group, wherein each group comprises a plurality of peripheral blood samples isolated from human body and derived from different people; respectively extracting DNA from each peripheral blood sample to obtain DNA liquids to be detected; determining the DNA contents and the DNA integrity in the DNA liquids to be detected, detecting whether the sample is qualified, and performing the next step if the sample is qualified; constructing a gene library by using a multiplex PCR technology, detecting whether the gene library is qualified, and performing the next step if the gene library is qualified; carrying out sequencing on the gene library by using a high-throughput sequencing technology; and analyzing the sequencing results, and constructing the systemic lupus erythematosus map model. According to the construction method of the systemic lupus erythematosus map model of the present invention, the design is reasonable and feasible, and the SLE related information adopted as the middle results can be effectively obtained.

The invention belongs to the field of biomedicine, in particular to application of CD200 or CD200 fusion protein for preparing systemic lupus erythematosus psychotherapeutic drugs. When sufficient exogenous CD200 molecules are given from external bodies, developmental deficits of adjusting T cell of systemic lupus erythematosus patients can be corrected, developmental differentiation of Th17 is reduced, migration chemotaxis functions of the DC is restrained, and the CD200 molecules are indicated to have potential therapeutic value. Preparation of high affinity CD200 recombinant protein is a conventional technique in the field, application is simple, therapeutical effects can be expressed through adjustment of internal body on the adjusting T cell, the Th17 cell and the CD cell in a multi-link mode, and novel psychotherapeutic drugs of systemic lupus erythematosus can be prepared.

The invention discloses a coumaronochromones compound as shown by a formula 1. Pharmacological experiments show that the coumaronochromones compound has significant inhibitory action on the proliferation of B lymphocytes and T lymphocytes, and can be used for preparing immunosuppressive agents or medicaments for treating various immunologic diseases such as rheumatoid arthritis, lupus erythematosus and the like, and the medicaments for treating B cell type chronic lymphocytic leukemia. The invention also provides a preparation method.

The invention belongs to the technical field of medicine, and particularly relates to a peptidylarginine deiminase PAD4 inhibitor compound shown in a formula (I) or pharmaceutically acceptable salts,stereoisomers and tautomers thereof, as well as pharmaceutical compositions, pharmaceutical preparations and application thereof. X, Y, R1, R2, R3, R4, R5, R7, R8, R9, ring B and m are as defined in the specification. The compound has inhibitory effect on peptidylarginine deiminase PAD4, and can be used for treating various diseases, such as rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, multiple sclerosis, cystic fibrosis, cancer, cutaneous lupus erythematosus, asthma and psoriasis.

This invention provides compositions and methods for preventing inflammatory diseases of the joints, including rheumatoid and osteoarthritis, tendonitis, bursitis, inflammation of the ligament, synovitis, gout, and systemic lupus erythematosus, wherein the methods include injecting into the inflamed joint a therapeutic anti-inflammatory composition comprising a bacterial or viral IL-10 expression construct, wherein the IL-10 expression construct comprises a bacterial or viral backbone and a nucleic acid sequence encoding interleukin-10.

The invention discloses a traditional Chinese medicine composition for treating systemic lupus erythematosus, which comprises the following raw materials in parts by weight: 8-10 parts of astragalus, 2-4 parts of prepared rehmannia root, 6-7 parts of rhizoma anemarrhenae, 4-6 parts of scutellariae barbatae, 2-4 parts of radix clematidis, 1-3 parts of semen lepidii, 5-6 parts of calyx kaki, 2-4 parts of cornus officinalis, 6-8 parts of radix aconiti preparata, 4-6 parts of selfheal, 1-3 parts of rhzizoma drynariae, 2-4 parts of Japanese raspberry root, 5-7 parts of caulis spatholobi, 4-5 parts of straight ladybell root, 2-4 parts of radix polygonati officinalis, 6-8 parts of atractylodes macrocephala, 2-5 parts of medicated leaven, 1-3 parts of ampelopsis grossedentata and 3-4 parts of chinquapin bark and leaf. The traditional Chinese medicine composition adopts purely natural traditional Chinese medicines as raw materials, and achieves the effects of removing toxin, eliminating spots, tonifying the heart and spleen, tonifying qi and yin, warming the kidneys, tonifying Yang, strengthening the spleen, soothing the liver and the like through the combination of the traditional Chinese medicines, and has a good curative effect on systemic lupus erythematosus. Clinical trials prove that the effective rate of the traditional Chinese medicine composition is up to 99% and the recovery rate of the traditional Chinese medicine composition is up to 94.2%.

The invention relates to a Chinese medicine for treating the systemic lupus erythematosus, particularly the lupus nephritis and a method for preparing the same. The medicine consists of the following components of oldenlandia diffusa, barbat skullcap, redroot gromwell, glutinous rehmannia, root of red-rooted salvia, motherwort and scorpion. The medicine has effects of clearing away the heat-evil and expelling superficial evils and activating blood circulation to dissipate blood stasis and is mainly used to treat the systemic lupus erythematosus, particularly the lupus nephritis; moreover, by matching Western medicines such as glucocorticoid and immunodepressant, etc., the medicine can be used to jointly treat the systemic lupus erythematosus, which can improve the effect of the hormone and the immunodepressant in curing the systemic lupus erythematosus, lower the incidence rate of infecting the complication, lower the recurernce rate and the death rate and have the important clinical meaning. The medicine of the invention can be made in all medicament forms for clinical use, including the powder, the medicinal broth, the mixture, the oral taking liquid, the capsule, the pelletized granule and the concentrated pill, etc.

The invention relates to the field of pharmaceutical formulation, and in particular relates to a traditional Chinese medicine decoction for treating systemic lupus erythematosus. The traditional Chinese medicine decoction is characterized in that the bulk drug comprises the following components in parts by weight: 5-11 parts of tuckahoe, 8-14 parts of dodder, 5-11 parts of herba epimedii, 5-11 parts of Atractylis ovata, 8-14 parts of broom cypress fruit, 5-11 parts of codonopsis pilosula, 5-11 parts of Chinese thorowax, 6-12 parts of roasted liquorice, 6-12 parts of radix scutellariae, 6-12 parts of cornel, 5-9 parts of radix paeoniae rubra, 8-14 parts of southernwood, 8-14 parts of Eclipta alba, and 6-12 parts of rhizoma cimicifugae; and the 14 bulk drug ingredients are mixed, then soaked with water and decocted, and dregs are removed to obtain the filtrate. The traditional Chinese medicine decoction for treating systemic lupus erythematosus is low in cost and relatively high in treating effective rate, and has no obvious toxic side effect.

The invention relates to a new drug for curing systematic lupus erythematosus, which comprises a dropping pill and oral liquid. Three Chinese medicine ingredients of tripterygium wilfordii total terpene 5% to 25%, haematine 5% to 25%, and baras camphor 2% to 8% are mixed in parts to be added into 62% to 68% preparation findings, and the invention is prepared through a simple process. The new drug of the innvntion has a strong function of anti-systematic lupus erythematosus in a mouse systematic lupus erythematosus illness mould, thereby the invention which is used on human clinic has a stronger treatment and rejection capabilities, the three drugs mutually reflect to produce significant harmonization role, which confronts a side effect which is brought by total terpene of tripterygium wilfordii, and the invention is led to be a non-toxic and most promising medicament to resist systematic lupus erythematosus. The invention has the advantages of significant effect, little side effect, simple preparation process and low cost, which must become a first choice drug to resist systematic lupus erythematosus.

The invention relates to a gene diagnosis reagent kit for systemic lupus erythematosus. The gene diagnosis reagent kit comprises primers for amplification of the OASL gene, the IGS15 gene and the LY6E gene, and further comprises a primer for the house-keeping gene RPLPO and an amplification reagent. The gene diagnosis reagent kit overcomes the defects that an I type interferon induction gene lacks of specificity, the number of detection genes is large, much time and labor are consumed, and consumption is increased. A real-time fluorescence quantification PCR method is adopted, and the gene diagnosis reagent kit has the advantages of being fast, sensitive, accurate and the like; the expression of the LY6E gene, the ISG15 gene and the OASL gene is detected through a real-time fluorescence quantification PCR, improved interferon indexes are worked out, early diagnosis of an SLE patient is facilitated, an important basis and reference value can be provided for clinical disease confirmation, and thus early prevention and treatment of the disease are facilitated; the gene diagnosis reagent kit has application and popularization value.

The invention relates to the field of immunosuppressive drugs, in particular to application of IL-21 to prepare an immunosuppressor and a method for promoting a regulatory B cell (B10) to differentiate and IL-10 to secrete by IL-21. Related experimental results show that: IL-21 is mainly used for promoting IL-10 to secrete by inducing phosphorylation-STAT3 to activate; IL-10 generated by induction can inhibit proliferation of in-vitro T cells and has the immunosuppressive action; and IL-21 can be used as the cell factor of in-vitro amplification cells and can be further used for preparing drugs for treating autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, scleroderma and the like.

The invention discloses a medical usage of russula griseocarnosa polysaccharide in treatment of systemic lupus erythematosus. The russula griseocarnosa polysaccharide PRG1-2 has the advantages of adjusting the activity of T cell subset, reducing IL-10, ds-DNA antibody and urine protein, being obviously effective in treatment, safe and reliable. Provided is an application of the russula griseocarnosa polysaccharide PRG1-2 with a wide clinical application prospect in preparation of medicine for treating systemic lupus erythematosus.

The subject matter relates to Semaphorin 3A (Sema3A) and its use in treatment and prognosis of Systemic Lupus Erythematosus (SLE). Provided are, inter-alia, methods of treating a subject afflicted with SLE, comprising administering to the subject a pharmaceutical composition comprising isolated Sema3A. Further provided are methods for prognosis of SLE, comprising measuring Sema3A serum concentration in a subject in need thereof.

The invention provides a traditional Chinese medicine for treating lupus erythematosus, which comprises the following components in parts by weight: Astragalus 25-35, Polygonatum 12-18, Caulis Spatholobus 25-35, Gentiana chinensis 25-35, Snake 4-8, Salvia 25-35, Lianzixin 8-16, Polygonatum 6-12, White Ginseng 4-8, Paeoniae Alba 12-18, Angelica 12-18, Ligustrum lucidum 25-35, Rehmannia glutinosa 25-35, Coptis 4-8 . The traditional Chinese medicine for treating lupus erythematosus provided by the invention has the advantages of good effect, low recurrence rate, treating both symptoms and root causes, and effectively relieving the patient's pain.

The invention provides methods for treating SLE including renal SLE and methods of reducing risk of renal flare in individuals with SLE, and methods of monitoring such treatment. One method of treating SLE including renal SLE and reducing risk of renal flare in an individual with SLE involves the administration of an effective amount of an agent for reducing the level of anti-dsDNA antibody (such as a dsDNA epitope as in the form of an epitope-presenting carrier or an epitope-presenting valency platform molecule like LJP 394) to the individual. The invention further provides a method of treating renal flare and reducing risk of renal flare in an individual with SLE involving the reduction of the level of circulating anti-dsDNA antibodies in the individual and maintaining sustained reduction of circulating anti-dsDNA antibodies, optionally through administration of a dsDNA epitope to the individual.

The invention discloses a medicine for treating systemic lupus erythematosus. The medicine comprises 10-20 g of radix linderae, 10-20 g of cortex cinnamomi, 10-20 g of rhizoma alpiniae officinarum, 10-20 g of radix codonopsis, 10-20 g of cordyceps sobolifera, 10-20 g of oleum sesami, 10-20 g of agastache rugosa, 10-20 g of stephania epigeae, 10-20 g of chelidonium majus and 10-20 g of ophioglossumpedunculosum. The medicine has the advantages that the systemic lupus erythematosus can be effectively treated by the medicine, and the medicine can become effective fast and is free of side effect and applicable to people who are of different genders at different age groups.

The present invention relates to a composition for a systemic lupus erythematosus risk prediction. In detail, in case where copy number variants of 1q25.1, C4 and 10q21.3 loci occur, the variants are regarded as high-risk groups for a systemic lupus erythematosus through the composition. The composition of the present invention enables prediction for the risk of systemic lupus erythematosus as the copy number variants of the three loci have a synergy effect for a development of systemic lupus erythematosus. Furthermore, the present invention is a test-friendly method which reduces analytical errors which may be created due to a new equipment purchased or technological limitations as a PCR generally implemented in a inspection room of majority of hospitals is used. In addition, the present invention is able to apply a non-invasive method to a person to be tested. Ultimately, the present invention predicts the risk of systemic lupus erythematosus which will essentially contribute to delaying development of the disease or to preventing an aggravation of state.